Merck announced the completion of patient enrollment in the TRA 2˚P-TIMI 50 clinical trial, a Phase III, randomized, double-blind, placebo-controlled, multinational study of SCH 530348, the company’s investigational antiplatelet protease activated receptor-1 inhibitor.
StreetInsider.com